Objective: To determine the antiretroviral activity of the integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), cabotegravir (CAB) and bictegravir (BIC), against different subtypes as well as primary and acquired drug resistance mutations (DRMs) in a patient-cohort infected with diverse subtypes.
Introduction
Integrase strand transfer inhibitors (INSTIs) of the HIV type 1 (HIV-1) have high potency, durable efficacy and low toxicity [1] . Three approved INSTIs, raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG) have been approved by FDA and European Medicines Agency. INSTIs, bictegravir (BIC) and cabotegravir (CAB), are currently in phase III studies [2, 3] . The INSTIs DTG and BIC exhibit longer dissociation half-life in biochemical analyses of wild-type integrase/DNA complexes, resulting in a high genetic barrier to resistance [4, 5] . The high efficacy in clinical trials [6, 7] and in clinical care has prompted an increasing use of DTG in first-line antiretroviral therapy (ART).
The efficacy of the newer INSTIs (CAB and BIC) across various HIV-1 subtypes in vitro and ex vivo is however not well documented [8] . Similar to other antiretrovirals, the development of INSTIs was based to a large extent on clinical and virological data from HIV-1 subtype B (HIV-1B). Although HIV-1 subtype has not been considered as a predictor for ART failure, an AIDS Clinical Trial Group (ACTG) trial indicated HIV-1 subtype C (HIV-1C) as an independent predictor for viral treatment failure [9] , similar to our study of the Swedish InfCare HIV cohort in which a higher risk of viral failure was found in HIV-1C patients than in HIV-1B, despite developed clinical care, modern laboratory monitoring and focused adherence support performed at highly HIV-specialized infectious disease clinics [10] . Also, subtype-specific differences in drug resistance to first generation INSTIs have been reported [8] as well as in DTG cross-resistance pattern in patients failing RAL [11] . Further sequence and structure-based analyses showed that the subtype-specific effects were caused by polymorphisms across the subtypes, which significantly affected native protein activity, structure, function of the drug-mediated inhibition of the enzyme [12] .
The current study is aimed to analyze if subtype-specific differences exist between INSTIs (RAL, EVG, DTG, CAB and BIC) with regard to in-vitro and ex-vivo antiretroviral potency, using biochemical and virological assays. Furthermore, the presence of primary and major accessory drug resistance mutations (DRMs) as well as acquired DRMs was investigated in patients from Sweden to delineate any subtype-specific differences.
Material and methods
Cell lines, plasmids and antiretrovirals TZM-bl cells, plasmid pNL43 and RAL were obtained from the NIH AIDS Reagent Program. 293T cells were purchased from ATCC (Manassas, Virginia, USA). The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma, St. Louis, Missouri, USA), supplemented with 10% Fetal Bovine Serum and 2-mmol/l L-glutamine. EVG (Selleck-S2001) and DTG (Selleck-S2667) were purchased from Selleckchem (Selleck Chemicals, Munich, Germany). CAB and BIC were kindly provided by ViiV Healthcare/GSK (Research Triangle Park, North Carolina, USA) and Gilead Sciences (Foster City, California, USA), respectively.
Clinical specimens and data Stored plasma samples, used in the ex-vivo studies, were randomly selected from 24 INSTI-naive adult patients from Stockholm, Sweden [10] . The viruses were pure subtypes (HIV-1B n ¼ 6; HIV-1C n ¼ 14; A1 n ¼ 1) or circulating recombinant forms (CRFs) [01_AE (n ¼ 1); 02_AG (n ¼ 2)], as determined by near full-length sequencing using our earlier published protocol [13] .
In addition, integrase sequences, which had been obtained within routine clinical care through direct population sequencing of INSTI-naive (n ¼ 270) or INSTI-experienced (n ¼ 96) patients were included for analysis of primary, major accessory or acquired DRM. Among the INSTI-experienced patients, 74% (71/96) were on RAL, 7% (7/96) on EVG and 17% (16/96) on DTG, whereas two were experienced with both RAL and DTG. The resistance interpretation for RAL, EVG and DTG were based on the Stanford HIV resistance database [14] . For CAB, the presence of E138A/Q148R, E138K/Q148K, E138K/Q148R, G140C/Q148R, G140S/Q148R or Q148R/N155H was interpreted as high-level resistance [2] . If a virus contained only one of these mutations, it was assigned as potential low-level resistance. For BIC, the presence of E138K/Q148R, G140S/Q148R or N155H/Q148R was interpreted as high-level resistance [3] . If a virus contained only one of these mutations, it was assigned as potential low-level resistance. In addition, if the M50I/R263K mutation was present, we termed it as intermediate resistance to BIC [3] . 
Cloning and purification of integrase
The complete coding region of the integrase genes (HXB2: 4230-5096) of four randomly selected INSTInaive patients infected by HIV-1B, C, CRF01_AE and CRF02_AG, respectively, were cloned into the pRSFDuet-integrase vector with N-terminal H 6 -tag. Recombinant integrase proteins were expressed in BL21-DE3-RIL cells. The expression of the IN protein was induced by addition of 1-mmol/l IPTG in incubatorshaker for 3 h at 37 8C. The cells were harvested and resuspended in 20-mmol/l Tris-HCl pH 8.0, 1-mol/l NaCl, 4-mmol/l 2-Mercaptoethanol (bME), 5-mmol/l imidazole, 10-mmol/l 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate, 1-mmol/l phenylmethylsulfonyl fluoride and 0.15-mg/ml lysozyme. The homogenized and sonicated cells were centrifuged, and the IN proteins were purified by Ni-affinity chromatography.
Inhibition of 3
0 -end processing assay To assess the 3 0 -end processing activity of integrase (IN) in the presence or absence of INSTIs, a 21-mer oligonucleotide was annealed to a complementary 5-32 P-labeled 21-mer oligonucleotide that contained a 3 0 -end-CAGT sequence. The endonucleolytic cleavage of 3 0 -end GT, resulting in an exposed CA-dinucleotide at the 3 0 -end, was conducted by incubating 300-nmol/l IN, 2-nmol/l DNA substrate, in a buffer containing 20-mmol/l MOPS (3-(N-morpholino)propanesulfonic acid), pH 7.2, 25-mmol/l NaCL, 1-mmol/l MnCl 2 and 3-mmol/l bME. The cleavage products were resolved on a 16% polyacrylamide 8-mol/l urea gel. The cleavage of the GTdinucleotide resulted in a 19-mer product. The reactions were allowed to proceed for different times and stopped by adding of Sanger's gel loading solution (95% formamide, 0.01% bromophenol blue, 0.01% xylene cyanol and 25 mmol/l ethylenediaminetetraacetic acid). The fraction of cleaved GT-dinucleotide was calculated by measuring the 19-mer products, which were then plotted as a function of time. A time point representing the linear range of 3 0 -end processing reaction (90 min) was selected, and the 3 0 -endonuclease activity of INs was monitored with increasing concentrations of INSTIs (0-100 nmol/l). The gels were exposed to PhosphoImager (GE Healthcare, North Richland Hills, Texas, USA), scanned on Typhoon FLA 700 (GE Healthcare), and the radioactive bands were quantitated by ImageQuant 5.2 (GE Healthcare). The amount of 3 0 -end excision products (19-mer) was plotted as the function of INSTI concentration, and the data were fit to a dose-response curve to estimate inhibition of 3 0 -end processing assay (IC 50-3P ) (three replicates).
Inhibition of strand-transfer activity assay
The inhibition of strand transfer activity in the presence INSTIs was assessed in gel-based assay. This assay separates the products of the strand-transfer reaction, which are longer than the 5 0 -32 P-labeled 19-mer substrate. Briefly, a 32 P-5 0 -end-labeled 19-mer single-stranded DNA (ssDNA) was annealed to a complementary 21-mer ssDNA. The 19-mer substrate has a CA-dinucleotide exposed for the INST reaction. Three hundred nmol/l IN was first incubated with 2 nmol/l 32 P-5 0 -end-labeled 19-mer for 15 min followed by addition of 500 nmol/l unlabeled 31 base-pair long double-stranded DNA and 1 mmol/l MnCl 2 . The reaction was allowed to proceed for 90 min in the presence of increasing concentrations of INSTIs (0-25 nmol/l) followed by stopping by Sanger's gel loading solution. The products were resolved on a 16% polyacrylamide 8 mol/l urea gel. The gels were exposed to PhosphoImager (GE Healthcare), scanned and quantitated as described above. The radioactive bands corresponding to products of greater than 19-mer were results of the IN strand-transfer reaction. These bands were quantitated and plotted as the function of INSTI concentration. The data were fitted to a dose-response curve to determine inhibition of strand-transfer activity assay (IC 50-ST ) of IN proteins for strand-transfer reaction (three replicates).
Cloning and recombinant virus production HIV-1 RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Germantown, Maryland, USA) from 140 ml of patients' plasma. The complementary deoxyribonucleic acid was generated using the SuperScript III RT enzyme (Invitrogen, Life Technologies, Woburn, Massachusetts, USA) with gene-specific primer 6231R, as described by us (Thermo Scientific, Waltham, Massachusetts, USA) [15] . The first-round PCR was performed using the high-fidelity KAPA HiFiHotStart Ready Mix (2Â) (KAPA Biosystem, Wilmington, Massachusetts, USA) with primers 0682F and 6231R primers. The second-round PCR was performed using 0702F-BssHII and 5798R-SalI which has BssHII and SalI restriction sites, respectively. The amplified product was restriction digested followed by gel purification using the QIAquickGel Extraction Kit (Qiagen). The gag-pol fragment (HXB2 : 0702-5798) was cloned in pNL43 Dgag-pol plasmid following digestion with BssHII and SalI (New England Biolab, Ipswich, Massachusetts, USA) and ligation with T4 DNA ligase (New England Biolab). The recombinant viruses were produced by transfecting the plasmids into the 293T cell line using FuGENE HD Transfection Reagent (Promega, Madison, Wisconsin, USA). All the molecular clones were sequenced bidirectionally. No primary DRM was observed in any of the clones. M50I was present in seven of the sequences from the HIV-1B (n ¼ 3) and the HIV-1C (n ¼ 4) strains.
Drug sensitivity assay
The drug sensitivity assay (DSA) was done by determining to which extent the five INSTIs inhibited the replication of our 24 recombinant viruses in the TZM-bl cells. Briefly, serial dilutions of the drugs spanning from 10 to 0.0001 mmol/l were added in triplicate in 96-well plates in complete DMEM media containing TZM-bl cells, followed by infection with a reference virus (NL43) or the corresponding patient-derived recombinant viruses (HIV-1B: n ¼ 6; HIV-1C: n ¼ 14; HIV-1A1: n ¼ 1; HIV-1CRF_01AE: n ¼ 1; HIV-1CRF_AG: n ¼ 2) at a multiplicity of infection of 0.05 IU/cells in the presence of 10 mg/ml concentration of diethylaminoethyl. Virus replication was quantified by measuring Renilla luciferase activity (relative light units) using Bright-Glo Luciferase Assay System (Promega). Drug concentrations required for inhibiting virus replication by 50% (EC 50 ) were calculated by a dose-response curve using nonlinear regression analysis (GraphPad Prism, version 5.01; GraphPad Software, La Jolla, California, USA). Each assay was performed using two to four biological replicates in triplicate.
Statistical analysis and data visualization
Statistical analysis was performed using an in-house R script or in GraphPad Prism, version 5.01 (GraphPad Software). The clustering analysis of the EC 50 fold-drug change of the patients-derived recombinant viruses against the control virus NL4-3 was performed using Qlucore Omics Explorer version 3.2 (Qlucore AB, Lund, Sweden). Comparisons of the EC 50 were conducted by the either Wilcoxon signed-rank test (for paired data), student t test and Mann-Whitney U test (for unpaired data) (between two groups) or analysis of variance (ANOVA) using the Kruskal-Wallis test by ranks (among three groups) where appropriate. A P value less than 0.05 considered significant.
Results
In-vitro inhibition of strand transfer and 3 0 -end processing activities The IC 50-ST for strand transfer inhibition of RAL, EVG, DTG, CAB and BIC is shown in Fig. 1a . RAL had higher IC 50-ST than the other INSTIs in all subtypes (P < 0.001). The drug-specific comparison showed that RAL had comparable potency (IC 50-ST ) for 01_AE and 02_AG but better potency for HIV-1C (P ¼ 0.047) when compared with HIV-1B. In contrast, EVG had relatively higher IC 50-ST for HIV-1C (P ¼ 0.016) and 02_AG (P ¼ 0.02). DTG showed lower IC 50-ST for HIV-1C than HIV-1B (P ¼ 0.003). For CAB, the non-B subtypes showed lower IC 50-ST (P ¼ 0.043, 0.027 and 0.026 for HIV-1C, 01_AE and 02_AG, respectively) compared with HIV-1B. For BIC, no difference was found between HIV-1B and HIV-1C, but a lower IC 50-ST was found for 01_AE and 02_AG (P ¼ 0.017 and 0.045, respectively) compared with HIV-1B.
INSTIs also inhibit 3
0 -end processing activity albeit at a lower efficiency than strand transfer activity. Hence, we determined IC 50-3P for all the IN against all the drugs (Fig. 1b) . All INSTIs had a $10-fold higher IC 50-3P for the 3 0 -end processing reaction compared with the strand transfer reaction.
Drug sensitivity assay
The ex-vivo DSA was performed using recombinant HIV-1B (n ¼ 6), HIV-1C (n ¼ 14) and A-like (A1, 01_AE and 02_AG; n ¼ 4) viruses, derived from INSTI naive patients (Fig. 2a) (Fig. 2b) . Although performing ANOVA among the group (Fig. 2c-g ), no statistical significance has been observed among the groups in RAL (Fig. 2c) , EVG (Fig. 2d) , CAB (Fig. 2f) and BIC (Fig. 2g) . However, in DTG, there was statistical difference as Alike viruses gave better ex-vivo potency than HIV-1B (P ¼ 0.019) and HIV-1C (P ¼ 0.011) (Fig. 2e) . 0 -end processing of raltegravir, elvitegravir, dolutegravir, cabotegravir and bictegravir. The data indicated that the inhibition of 3 0 -end processing was much weaker relative to the inhibition of strand transfer activity across subtypes. HIV-1 subtype B, subtype C, CRF01_AE and CRF02_AG, were used.
had at least one major accessory DRM: T97A (n ¼ 3), E157Q (n ¼ 12), or A128T (n ¼ 2). The A128T is a nonpolymorphic mutation selected in vitro by EVG, but does not appear to reduce INSTI susceptibility ex vivo. The naturally occurring polymorphism M50I was found in 49 (18%) of the INSTI-naive patients. None of the INSTI-naive patients had nucleoside reverse transcriptase Inhibitor (NRTI) mutations; however, three individuals had non-nucleoside reverse-transcriptase inhibitors (NNRTIs), DRM (V106M, K103N, G190A).
Thirteen of the 17 INSTI-naive patients initiated an INSTI-based regimen with either DTG (n ¼ 11) or RAL (n ¼ 2). Among them, seven initiated 2 NRTI þ DTG once-daily (OD), six switched from a 2 NRTI þ 1 NNRTI regimen to an INSTI containing ART (DTG OD n ¼ 3; DTG twice-daily n ¼ 1) with either abacavir/ lamivudine or tenofovir disoproxil/emtricitabine. The reasons for switching the regimen was either failing on 2 NRTI þ 1 NNRTI therapy (n ¼ 4) or due to side effects with undetectable viremia (n ¼ 2). The patients who failed an NNRTI (n ¼ 4)-based regimen had one to three regimens prior to initiation of the INSTI. Among the NNRTI failure patients, two patients had K103N and V106M/Y188CH mutation, respectively. No NRTI or protease inhibitors mutations were found. The HIV-1 RNA load was also checked after 6 months. Two RALtreated patients with E157Q and T97A mutations, respectively, failed to suppress viremia at month 6. Eight of the nine patients on DTG, who had a major accessory mutation just before switch, showed low-level viremia at month 6. One of the two patients who switched with suppressive viremia, maintained undetectable viral load, but one (with T97A) had a viral blip at month 6 (57 copies/ml) (Fig. 3a) . Sequencing of samples collected 1216 and 1038 days earlier from these two patients showed that they had E157Q and the T97A mutations, respectively. Taken together, 11 of 13 INSTI-naive patients with INSTIs DRM before initiating RAL or DTG did not reach undetectable viremia after 6 months.
Among the INSTI-experienced patients failing on ART (n ¼ 96), 24% (23/96) had major INSTI DRM (Fig. 3b ) and all of them had failed RAL. Four (17%) of the 23 patients were predicted to be fully susceptible to DTG, CAB and BIC. Five patients (21%) with multiple
were predicted to have high-level cross resistance to DTG, CAB and BIC, although no phenotypic assessment has confirmed this observation [2, 3] . The DRM profiles were similar in the HIV-1B and non-B subtypes.
Discussion
An increasing body of data suggests that the efficacy of the ART and the HIV-1 drug resistance pattern varies depending on the HIV-1 subtype. However, whether this holds true for second generation INSTIs is not well studied. Hence, this study was designed to evaluate the potency of INSTIs in different HIV-1 subtypes, using a combination of biochemical and cell culture assays. Overall, our data suggested that all of the three newer INSTIs (DTG, CAB, BIC) had a higher antiretroviral potency against HIV-1B as well as non-B subtypes compared with the older INSTIs (RAL and EVG), and no significant subtype-specific difference in antiretroviral potency of the individual INSTIs was observed.
The integration of HIV DNA into host genome requires 3 0 -end processing and strand transfer reaction [16] . Similar to previous reports for RAL, EVG [17] , DTG [18] and BIC [3] , our data showed that the INSTIs are not as efficient in inhibiting 3 0 -end processing as they are in inhibiting strand transfer activity for all subtypes, as expected. It has been reported that 3 0 -end processing is as efficient in HIV-1 group O as in HIV-1 group M [19] ; however, to our knowledge, no comparison among different HIV-1 subtypes has been done earlier. Our results suggest that the IC 50-3P for HIV-1C IN is highest among the tested subtypes for all INSTIs, except for BIC. As the selectivity for strand transfer over 3 0 -end processing is driven by key enzyme-DNA interactions in the active site [18] , it is possible that DNA/IN interactions in HIV-1C integrase differ from other subtypes. This interpretation could possibly be further supported by our results that the RAL IC 50-ST for HIV-1B and HIV-1A-like were significantly higher than the IC 50-ST of other INSTIs, but similar IC 50-ST were obtained for HIV-1C for all INSTIs. It must be pointed out here that the IC 50-3P values were determined with one integrase from four different subtypes. Hence, it is possible that these IC 50 values may change when several INs from different subtypes are cloned and inhibition assays are conducted. However, IC 50-3P values from our independently conducted assays for each subtype were consistent suggesting 'meaningful' differences.
In our DSA, we noted that DTG, CAB and BIC had a higher potency than RAL and EVG independent of subtype, which is in line with recent studies on BIC [3] and CAB [2, 20] . Our cluster analysis also suggested that Fig. 3. (a) HIV type 1 RNA load at initiation of integrase strand transfer inhibitor containing combination therapy and after 6 months. Log-transformed RNA copies/ml is presented for 11 integrase strand transfer inhibitor-naive patients with a major accessory mutation (T97A, A128T or E157Q), who initiated dolutegravir containing triple therapy. (b) Drug resistance profile and level of resistance on patients failing raltegravir-based therapy. For raltegravir, elvitegravir and dolutegravir drug resistance mutations were identified according to Stanford HIV resistance database [14] , whereas for cabotegravir and bictegravir, the mutations were identified as reported in the literature (see method section) [3, 20] .
no differences existed in activity against the subtypes analyzed for CAB, and BIC, although a better potency for A-like viruses were observed for DTG.
A natural polymorphism M50I was found in 18% of INSTI-naive patients, which is in-line with the prevalence of this mutation in different subtypes in the Stanford HIV drug resistance database, ranging between 3 and 33% (median 10.5%) [14] . Mutation R263K mutation has been shown to confer two-fold to five-fold resistance to DTG, with decreased viral replication and strand transfer activity [21] . In breakthrough selections, M50I emerges after R263K [3] and provides replication advantage to R263K containing virus. A selection of R263K/M50I has been described in virus outgrowth assay for BIC that resulted 2.8-fold reduction of BIC-susceptibility, but M50I alone did not have any effect [3] . Seven of our 24 recombinant viruses had preexisting M50I, but the EC 50 for all INSTIs were very low confirming no effect of this mutation alone ex vivo.
Although analyzing a large number of integrase sequences from INSTI-naive patients, we observed only one patient (0.4%) with a primary DRM. Instead, 17 (6.3%) patients had major INSTI accessory mutations (E157Q, T97A and A128T). These accessory mutations should not be interpreted as transmitted drug resistance and the importance of such natural polymorphisms is disputed. However, of 13 patients with these mutations, who were switched to RAL (n ¼ 2) or DTG (n ¼ 11) containing ART, only two had undetectable viremia after 6 months. Obviously, this is an anecdotal observation, and other factors such as decreased adherence may also have contributed. However, the slow decline in viral load is still surprising to us, in view of the usual rapid decline when INSTIs are given and that the rate of undetectable viremia in the Swedish InfCare cohort is 95% after 6 months or more on ART [22] .
In conclusion, our study showed that the three newer INSTIs (DTG, CAB and BIC) had higher antiretroviral potency not only in HIV-1B but also in non-B subtypes compared with the first two approved INSTIs RAL and EVG. Moreover, no significant difference among the newer INSTIs was seen with regard to their efficacy against different subtypes. Thus, DTG, CAB and BIC are attractive options for countries where non-B subtype infections are prevalent. Our analyses of patient-derived sequences from INSTI-naive individuals in clinical settings were reassuring with respect to the very low prevalence of primary INSTI DRM, despite the use of RAL and EVG since 2006. Furthermore, our sequencing results suggest that a relatively high rate of major accessory INSTI DRMs requires follow-up for their long-term impact on the outcome of INSTI-based ART.
